Morphic Holding, Inc. (MORF) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Waltham, MA, United States. Le PDG actuel est Praveen P. Tipirneni.
MORF a date d'introduction en bourse 2019-06-27, 128 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $2.86B.
Morphic Holding, Inc. is a biopharmaceutical company focused on discovering and developing oral small-molecule integrin therapeutics to treat autoimmune, cardiovascular, metabolic, fibrotic, and oncologic diseases. The company's lead candidate, MORF-057, is an α4β7-specific integrin inhibitor currently in Phase 1 clinical trials for inflammatory bowel disease, with preclinical programs targeting idiopathic pulmonary fibrosis and other fibrotic conditions. Morphic is also advancing programs in αvβ6 for fibrotic diseases and αvβ8 for solid tumors through its proprietary integrin technology platform. The company has established research collaborations and licensing agreements with major partners including AbbVie, Janssen Pharmaceuticals, and Children's Medical Center Corporation to accelerate integrin-based drug development. Founded in 2014 and headquartered in Waltham, Massachusetts, Morphic leverages its integrin technology expertise to address significant unmet medical needs across multiple therapeutic areas.
